@article{45c5493619b34c9fb5f14adb534a6147,
title = "Editorial: risky business. What do sufferers' perceptions of risk from interventions for irritable bowel syndrome really mean?",
author = "Quigley, {Eamonn M.M.}",
note = "Funding Information: Declaration of personal interests: EMM Quigley served as a consultant to 4D Pharma, Precisionbiotics, Novozymes, Salix and Vibrant and has received research funding from 4D Pharma, Biomerica and Vibrant. Declaration of personal interests: None.",
year = "2022",
month = may,
doi = "10.1111/apt.16909",
language = "English (US)",
volume = "55",
pages = "1218--1219",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley",
number = "9",
}